GNT Pharma: Clinical Trials

3 trials sponsored by GNT Pharma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 unknown. 2 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 22Unknown 2
Phase 31Unknown 1

Follow GNT Pharma: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Rescues On Reperfusion Damage In Cerebral Infarction by Nelonemdaz
Neu2000KWL group, Placebo group - Ischemic Stroke
Phase 3UnknownGNT Pharma4962021-12-252022-09-26
Antioxidant and NMDA Receptor Blocker Wins Anoxic Brain Damage of KorEa OHCA Patients
Neu2000KWL High-dose group, Neu2000KWL Low-dose group, Placebo - Cardiac Arrest
Phase 2UnknownGNT Pharma1502018-11-292019-03-06
Safety and Optimal Neuroprotection of neu2000 in Ischemic Stroke With Endovascular reCanalizion (SONIC)
Neu2000KWL High-does group, Neu2000KWL Low-does group, Placebo - Ischemic Stroke
Phase 2UnknownGNT Pharma2102016-07-012017-07-13

Conditions studied

Ischemic Stroke (2)  ·  Heart Arrest (1)  ·  Out-of-Hospital Cardiac Arrest (1)

Interventions

Population Groups (1)

Countries

South Korea (3)

Top investigators

Ji Man Hong, MD, PhD (1)  ·  Jin-Ho Choi, MD (1)  ·  Sun Uck Kwon, MD, PhD (1)

Results publications

PMID 30005644, PMID 35871083, PMID 36065810, PMID 36746385, PMID 39874036, PMID 39899673